Ernexa Therapeutics Shares Outstanding History (ERNA)
Ernexa Therapeutics reported 7.9M shares outstanding at the end of fiscal 2025.
View full Ernexa Therapeutics company overviewErnexa Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 7.9M | 4.4M | +129.25% |
| 2024 | 2024-12-31 | 3.4M | −2.0M | −36.67% |
| 2023 | 2023-12-31 | 5.4M | 283,000 | +5.52% |
| 2022 | 2022-12-31 | 5.1M | 2.5M | +97.12% |
| 2021 | 2021-12-31 | 2.6M | 2.6M | — |
| 2020 | 2020-12-31 | 0 | −36,262.5 | — |
| 2019 | 2019-12-31 | 36,262.5 | 325 | +0.90% |
| 2018 | 2018-12-31 | 35,937.5 | 4,425 | +14.04% |
| 2017 | 2017-12-31 | 31,512.5 | 3,250 | +11.50% |
| 2016 | 2016-12-31 | 28,262.5 | 5,150 | +22.28% |
| 2015 | 2015-12-31 | 23,112.5 | −1.1M | −98.00% |
| 2014 | 2014-12-31 | 1.2M | 171,512.5 | +17.45% |
| 2013 | 2013-12-31 | 983,112.5 | 94,075 | +10.58% |
| 2012 | 2012-12-31 | 889,037.5 | 888,275.913 | +116634.78% |
| 2011 | 2011-12-31 | 761.588 | 2.2 | +0.29% |
| 2010 | 2010-12-31 | 759.388 | — | — |
Ernexa Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.2M | −6.3M | −84.36% |
| Q1 2026 | 2026-03-31 | 1.2M | −51.1M | −97.77% |
| Q4 2025 | 2025-12-31 | 314,000 | −51.1M | −99.39% |
| Q3 2025 | 2025-09-30 | 7.8M | 2.4M | +45.06% |
| Q2 2025 | 2025-06-30 | 7.5M | 2.1M | +38.29% |
| Q1 2025 | 2025-03-31 | 52.3M | 46.8M | +865.80% |
| Q4 2024 | 2024-12-31 | 51.4M | 46.0M | +849.83% |
| Q3 2024 | 2024-09-30 | 5.4M | 1,000 | +0.02% |
| Q2 2024 | 2024-06-30 | 5.4M | 1,000 | +0.02% |
| Q1 2024 | 2024-03-31 | 5.4M | 283,000 | +5.52% |
| Q4 2023 | 2023-12-31 | 5.4M | 283,000 | +5.52% |
| Q3 2023 | 2023-09-30 | 5.4M | 2.5M | +83.89% |
| Q2 2023 | 2023-06-30 | 5.4M | 2.5M | +88.28% |
| Q1 2023 | 2023-03-31 | 5.1M | 2.3M | +78.48% |
| Q4 2022 | 2022-12-31 | 5.1M | 2.5M | +97.11% |
| Q3 2022 | 2022-09-30 | 2.9M | 339,809.1 | +13.06% |
| Q2 2022 | 2022-06-30 | 2.9M | 638,080.9 | +28.54% |
| Q1 2022 | 2022-03-31 | 2.9M | 797,300.1 | +38.42% |
| Q4 2021 | 2021-12-31 | 2.6M | 2.6M | — |
| Q3 2021 | 2021-09-30 | 2.6M | 2.6M | +6952.01% |
| Q2 2021 | 2021-06-30 | 2.2M | 2.2M | +5986.78% |
| Q1 2021 | 2021-03-31 | 2.1M | 2.0M | +5574.09% |
| Q4 2020 | 2020-12-31 | 0 | −36,262.5 | — |
| Q3 2020 | 2020-09-30 | 36,900 | 712.5 | +1.97% |
| Q2 2020 | 2020-06-30 | 36,725 | 36,688.975 | +101843.10% |
| Q1 2020 | 2020-03-31 | 36,575 | 600 | +1.67% |
| Q4 2019 | 2019-12-31 | 36,262.5 | 325 | +0.90% |
| Q3 2019 | 2019-09-30 | 36,187.5 | 287.5 | +0.80% |
| Q2 2019 | 2019-06-30 | 36.025 | −35,788.975 | −99.90% |
| Q1 2019 | 2019-03-31 | 35,975 | 4,462.5 | +14.16% |
| Q4 2018 | 2018-12-31 | 35,937.5 | 4,425 | +14.04% |
| Q3 2018 | 2018-09-30 | 35,900 | 35,868.55 | +114049.44% |
| Q2 2018 | 2018-06-30 | 35,825 | 35,793.588 | +113946.96% |
| Q1 2018 | 2018-03-31 | 31,512.5 | 462.5 | +1.49% |
| Q4 2017 | 2017-12-31 | 31,512.5 | 3,250 | +11.50% |
| Q3 2017 | 2017-09-30 | 31.45 | −23,081.05 | −99.86% |
| Q2 2017 | 2017-06-30 | 31.413 | −23,081.088 | −99.86% |
| Q1 2017 | 2017-03-31 | 31,050 | −1.1M | −97.31% |
| Q4 2016 | 2016-12-31 | 28,262.5 | −1.1M | −97.55% |
| Q3 2016 | 2016-09-30 | 23,112.5 | −1.1M | −98.00% |
| Q2 2016 · Jun 30 | 2016-06-30 | 23,112.5 | −1.1M | −98.00% |
| Q2 2016 · Jun 16 | 2016-06-16 | 1.2M | 339.675 | +0.03% |
| Q1 2016 | 2016-03-31 | 1.2M | 725 | +0.06% |
| Q4 2015 | 2015-12-31 | 1.2M | 862.5 | +0.07% |
| Q3 2015 | 2015-09-30 | 1.2M | 1,475 | +0.13% |
| Q2 2015 | 2015-06-30 | 1.2M | 9,362.5 | +0.82% |
| Q1 2015 | 2015-03-31 | 1.2M | 170,725 | +17.35% |
| Q4 2014 | 2014-12-31 | 1.2M | 171,512.5 | +17.45% |
| Q3 2014 | 2014-09-30 | 1.2M | 1.2M | +128491.53% |
| Q2 2014 | 2014-06-30 | 1.1M | 1.1M | +127913.80% |
| Q1 2014 | 2014-03-31 | 984,037.5 | 983,143.55 | +109977.47% |
| Q4 2013 | 2013-12-31 | 983,112.5 | 982,223.463 | +110481.67% |
| Q3 2013 | 2013-09-30 | 897.163 | 9.1 | +1.02% |
| Q2 2013 | 2013-06-30 | 895.05 | 6.988 | +0.79% |
| Q1 2013 | 2013-03-31 | 893.95 | 6.475 | +0.73% |
| Q4 2012 | 2012-12-31 | 889.038 | 127.45 | +16.73% |
| Q3 2012 | 2012-09-30 | 888.063 | 126.725 | +16.65% |
| Q2 2012 | 2012-06-30 | 888.063 | 126.912 | +16.67% |
| Q1 2012 | 2012-03-31 | 887.475 | 128.087 | +16.87% |
| Q4 2011 | 2011-12-31 | 761.588 | — | — |
| Q3 2011 | 2011-09-30 | 761.338 | — | — |
| Q2 2011 | 2011-06-30 | 761.15 | — | — |
| Q4 2010 | 2010-12-31 | 759.388 | — | — |
Ernexa Therapeutics shares outstanding trends
Over the last five reported fiscal years, Ernexa Therapeutics's shares outstanding moved from 0 to 7.9M, a change of 7.9M. The latest reported quarter, Q2 2026, shows 1.2M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ernexa Therapeutics filings at SEC.gov ↗